| Trial ID: | L4644 |
| Source ID: | NCT01574508
|
| Associated Drug: |
Transient Continuous Subcutaneous Insulin Infusion
|
| Title: |
Continuous Subcutaneous Insulin Infusion strAtegy Versus Multiple Daily Insulin Injections strAtegy
|
| Acronym: |
CAMACS
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Transient Continuous Subcutaneous Insulin Infusion|DRUG: Transient Multiple Daily Insulin Injections
|
| Outcome Measures: |
Primary: Glycated hemoglobin levels, The different influence of two intensive insulin treatment strategies: CSII and MDI on the change of glycated hemoglobin levels during two weeks intensive insulin treatment period and 1 year after the intensive treatment., During 2 weeks intensive insulin treatment period and 1 year after the intensive treatment.|Glycated albumin levels, The different influence of two intensive insulin treatment strategies: CSII and MDI on the change of glycated albumin levels during two weeks intensive insulin treatment period and 1 year after the intensive treatment., During 2 weeks intensive insulin treatment period and 1 year after the intensive treatment. | Secondary: The glucose levels, The different influence of CSII and MDI on the change of plasma glucose levels during 2 weeks intensive treatment and 1 year after treatment, During 2 weeks intensive treatment and 1 year after treatment|Episode of hypoglycemia, The different influence of CSII and MDI on Episode of hypoglycemia during 2 weeks of intensive treatment and 1 year after treatment, During 2 weeks of intensive treatment and 1 year after treatment|Body weight, The different influence of CSII and MDI on Body weight during 2 weeks intensive treatment and 1 year after treatment, During 2 weeks intensive treatment and 1 year after treatment|Biochemical parameters and inflammatory factors, The different influence of CSII and MDI on the change of biochemical parameters and inflammatory factors during 2 weeks intensive treatment and 1 year after treatment, During 2 weeks intensive treatment and 1 year after treatment|C peptide levels, The different influence of CSII and MDI on the change of C peptide levels during 2 weeks intensive treatment period and 1 year after treatment, During 2 weeks intensive treatment and 1 year after treatment|Number of participants with adverse events, The number of Participants with adverse events in different intensive treatment strategies (CSII or MDI) during 2 weeks intensive treatment period and 1 year after treatment., During 2 weeks intensive treatment and 1 year after treatment
|
| Sponsor/Collaborators: |
Sponsor: Shanghai Jiao Tong University School of Medicine
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
120
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2011-12
|
| Completion Date: |
2014-12
|
| Results First Posted: |
|
| Last Update Posted: |
2013-05-06
|
| Locations: |
Ruijin hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, Shanghai, 200025, China
|
| URL: |
https://clinicaltrials.gov/show/NCT01574508
|
